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Abstract  19 
During recent years the exopolysaccharides (EPS) produced by some strains of lactic acid 20 
bacteria and bifidobacteria have attracted the attention of researchers, mainly due to their potential 21 
technological applications. However, more recently it has been observed that some of these EPS 22 
present immunomodulatory properties, which suggest a potential effect on human health. Whereas 23 
EPS from lactic acid bacteria have been studied in some detail, those of bifidobacteria largely 24 
remain uncharacterized in spite of the ubiquity of EPS genes in Bifidobacterium genomes. In this 25 
review we have analysed the data collected in literature about the potential immune modulating 26 
capability of EPS produced by lactic acid bacteria and bifidobacteria. From this data analysis, as 27 
well as from results obtained in our group, a hypothesis relating the physico-chemical 28 
characteristics of EPS with their immune modulation capability was highlighted. We propose that 29 
EPS having negative charge and/or small size (molecular weight) are able to act as mild stimulators 30 
of immune cells, whereas those polymers non-charged and with a large size present a suppressive 31 
profile. 32 
 33 
 34 
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1. Introduction  38 
1.1. Bacterial EPS 39 
 The ability to produce exo-cellular polysaccharides is widespread throughout the microbial 40 
world, from some algae, fungi and yeasts to prokaryotes. In the last case, polymers produced by 41 
Archaea isolated from diverse, extreme environments (extremophiles) have been receiving special 42 
attention in recent times due to their potential applications [45]. However, several biopolymers 43 
produced by Bacteria, both Gram-positive and Gram-negative, are currently well studied and 44 
characterized due to their industrial, medical and biotechnological uses [38, 47, 68]. Besides, it is 45 
known that their ecological role, either in Archaea or Bacteria, is similar since these biopolymers 46 
are involved in cell protection to fight against harsh environmental conditions [24], and in niche 47 
colonization; for example exo-cellular polymers are key players in biofilm formation [22, 36]. In 48 
addition, some of these bacterial biopolymers are receiving renewed interest due to their biological 49 
functions, particularly their involvement in human health [37, 55]. 50 
Most bacteria are often covered by a layer of polysaccharides which is called glycocalyx 51 
[21]. These polymers can be linked to the cell surface by means of covalent bonds forming a 52 
capsule and therefore they are named capsular polysaccharides (CPS).  Other polymers are weakly 53 
attached to the surface, or are totally released into the surrounding environment, forming slime, and 54 
they are referred as exopolysaccharides (EPS).  This classification, according to cell location, is not 55 
clear [63] and more precise definitions have been collected in the literature [6]. For practical 56 
purposes, in the context of this article we will use the term EPS for both exo-cellular layers. In fact, 57 
these two types of EPS are carbohydrate polymers built from a reduced number of different 58 
monosaccharides (most common: glucose, fructose, galactose, rhamnose and fucose). However the 59 
presence of different isomers, linkage types and organic and inorganic monosaccharide substituents 60 
that could be combined in repeating units which have, as well, different degrees of polymerization 61 
and branching patterns, render a great variety of bacterial EPS. In another practical classification, 62 
bacterial EPS are divided into two main groups depending on whether a single monosaccharide type 63 
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is present in the polymer or more; they are the homopolysaccharides (HoPS) and 64 
heteropolysaccharides (HePS), respectively, which also differ in the number of enzymes and 65 
organization of genes involved in their synthesis [6, 56, 62]. Finally, depending on the substituents 66 
present in the repeating units of HePS, there are non-charged, charged or neutral polymers. Within 67 
the latter, of special mention are the “zwitterionic” EPS characterized to have both positively (e.g. 68 
free amine) and negatively (e.g phosphate or carboxylate) charged moieties within their repeating 69 
units [37]. These molecules have been reported to be able to modulate the immune system, both 70 
innate and adaptive response, although they are very rare among bacteria. To date, only two Gram-71 
positive pathogens, Streptococcus pneumoniae and Staphylococcus aureus, as well as the Gram-72 
negative Bacteriodes fragilis, a common member of the human intestinal microbiota, were reported 73 
as producers of such EPS [36]. Indeed, it has been indicated that the zwitterionic EPS, named 74 
polysaccharide A, from Bact. fragilis could play a key role in oral tolerance and in balancing the 75 
immune status associated with some infections or inflammatory disorders [50, 51, 52]. 76 
Some strains of Gram-positive bacteria such as Lactobacillus, a member of lactic acid 77 
bacteria (LAB) group, and Bifidobacterium are considered probiotics; that is “live microorganisms 78 
which when administered in adequate amounts confer a health benefit on the host” [15]. 79 
Worldwide, research on probiotics is one of the most interesting scientific fields due to its 80 
implication on human health, also representing a good opportunity for the industrial development of 81 
new products [3]. Some bifidobacteria and lactobacilli species share common habitats, for example 82 
animal mucosa such as the oral-gastrointestinal tract [34, 73]. However, the genomic G+C content 83 
separates Bifidobacterium (G+C > 50%) and Lactobacillus (G+C < 50%) in two taxonomic phyla: 84 
Actinobacteria and Firmicutes, respectively [16, 34, 66]. Nowadays, the capability of lactobacilli to 85 
synthesize EPS is well documented; in fact, some strains isolated from foods have been used for the 86 
manufacture of fermented dairy products from a long time ago [55]. The research interest in 87 
bifidobacterial EPS is more recent and there are data in literature that attribute some of the 88 
beneficial health effects produced by probiotic lactobacilli and bifidobacteria to their EPS. 89 
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Therefore, in this article we will review some traits of the EPS-producing phenotype in LAB and 90 
bifidobacteria and we will gather, as well, evidence that could give us clues to understand the 91 
capability of EPS to modulate immune response.    92 
 93 
1.2. Biosynthesis of EPS from LAB  94 
 To date, a wide variety of EPS synthesized by LAB belonging to both HoPS and HePS types 95 
have been described (for greater comprehension, read [55, 56]). The HoPS are composed either of 96 
D-glucose (-glucans and -glucans) or D-fructose (-fructans), which can be divided into subtypes 97 
depending on the position of the carbon involved in linkage. The synthesis of -glucans and -98 
fructans requires the presence of sucrose as substrate, which donates the corresponding glycosyl 99 
moiety to a polymer in formation in a reaction catalyzed by a single type of enzyme named 100 
glycansucrase [39, 72]. These extracellular enzymes are members of the glycoside hydrolase (GH) 101 
family, and are referred to as glucansucrases (family GH70) and fructansucrases (family GH68) 102 
involved in the polymerization of -glucans and -fructans, respectively. They can also catalyze the 103 
hydrolysis of sucrose and the synthesis of oligosaccharides when the acceptor molecule is other 104 
than glycans [28]. -glucans are less frequent in LAB and, to date, the few that have been described 105 
have the same structure: (13)--D-glucan with side ramifications of a single (12)-linked -D-106 
glucose. These -glucans are synthesized through a different mechanism in which another single 107 
enzyme type (glucosyltransferase), that does not use sucrose as substrate, is involved [11, 75, 76]. 108 
This enzyme belongs to the COG1215 membrane-bound glycosyltransferase family and topology 109 
predictions show that a conserved cytosolic domain is flanked by two and four transmembrane 110 
segments [76]. The sequences of the glucosyltransferases from a few LAB are homologous to that 111 
of the polysaccharide synthase (GenBank accession no. CAB51329) from S. pneumoniae serotype 112 
37 which produce the same structural capsular -glucan. In addition, by means of agglutination 113 
experiments using pneumococci serotype 37 anti-serum, the presence of this type of polymer was 114 
detected in some LAB [75, 76] as well as in propionibacteria [8, 11]. However, the mechanism of 115 
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-glucan synthesis by LAB is still not known; in Propionibacterium freudenreichii it seems that the 116 
homologous polysaccharide-synthase enzyme catalyzes the intracellular polymerization of glucose 117 
monomers, from nucleotide sugar precursors, and is able to carry out the export [8]. 118 
 HePS from LAB result from the polymerization of repeating units which are composed of 119 
monosaccharides and of organic- and inorganic-substituted monosaccharides. Most common sugars 120 
are D-glucose, D-galactose and L-rhamonose and, to a lesser extent, N-acetyl-glucosamine and N-121 
acetyl-galactosamine [56]. Fucose and ribose have been described in the repeating units of a few 122 
HePS [12, 33] and organic and inorganic molecules can also be present, for example, glucuronic 123 
acid [49], acetyl [71], glycerol-phosphate [78] and phosphate [70]. At the time of writing, 124 
combinations of 2 to 8 monomers have been described rendering more than 45 different structural 125 
repeating units determined by means of nuclear magnetic resonance (NMR) techniques. These 126 
different NMR structures are obtained from the variation in monomers, linkage type ( or ), 127 
position of the carbon involved in linkage, presence of different side chains, etc. [56, 58]. The 128 
complexity of the chemical and structural composition of the HePS repeating units is reflected in 129 
the organization of genes encoding proteins involved in their synthesis, which are organized in eps 130 
clusters.  In general, eps clusters from LAB have an operon structure with most genes oriented in 131 
one direction and having a high coding density and a highly conserved structural-functional 132 
organization. In general, LAB-eps clusters harbour genes coding for glycosyltransferases (GTF), 133 
which build the HePS repeating units, and proteins involved in the export-polymerization of the 134 
repeating units, in the HePS chain length determination, and in regulation of the full HePS 135 
biosynthesis process. Very often, mobile elements are located bordering these eps-clusters, which 136 
could explain the instability of HePS-production phenotype in some LAB [5, 10, 23, 56]. 137 
 138 
1.3. Biosynthesis of EPS from Bifidobacterium genus 139 
The EPS-production phenotype has been less studied in bifidobacteria than in LAB, 140 
probably due to the lack of known technological use for bifidobacterial polymers. However, in the 141 
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context of probiotics, research in EPS field is gaining interest since these polymers, as components 142 
of bacterial envelope, could be directly related with probiotic-host interactions, and therefore with a 143 
potential health benefit. Indeed, the first question to arise is whether bifidobacteria and non-food 144 
origin lactobacilli are able to synthesise EPS. Using culture-dependent techniques and a 145 
combination of phenotypic and genotypic screening, our group has demonstrated that lactobacilli 146 
and bifidobacteria from human origin (faeces) harbour eps genes and they are able to produce HePS 147 
under laboratory conditions [53, 59]. Similar results have recently been reported with another 148 
collection of bifidobacteria from human origin [46]. On the contrary, and as far as we know, 149 
synthesis of HoPS-type polymers have not been reported yet in strains of these genera isolated from 150 
human sources. Nevertheless, lactobacilli species isolated from duck and pig intestines were able to 151 
produced both glucan and fructan HoPS-types from sucrose [64]. By using animal models, it was 152 
inferred that HePS could be synthesised in vivo under the gastrointestinal conditions, either by 153 
lactobacilli or bifidobacteria [7, 14, 29]. Finally, a recent in silico analysis of bifidobacterial 154 
genomes underlines the ubiquitous presence of genes involved in the synthesis of HePS, which 155 
seems to be organized in cluster-like structures [30, 58]. However, the remaining, and challenging, 156 
task is to purify the in vivo synthesised EPS in order to understand their physico-chemical 157 
properties, which could help to answer why only some specific polymers have biological and 158 
functional properties.   159 
Up to now, only a few bifidobacterial polymers have been purified and fully characterised 160 
[58]. The EPS described in bifidobacteria are HePS-type, their monosaccharide constituents being 161 
those found for LAB-EPS; that is, glucose, galactose and rhamnose (Table 1). In B. animalis subsp. 162 
lactis, 3 out of 4 strains showed polymers with the same glucose- galactose- rhamnose ratio (about 163 
2.5: 2: 1, respectively). Only the EPS synthesised by strain IPLA-R1 was different, since the 164 
rhamnose content increased; this was due to the production of another EPS-fraction of high 165 
molecular weight (HMW, about 3x10
6
 Da) having 50% of rhamnose in its repeating unit structure 166 
[31]. The strain IPLA-R1, also named A1dOxR, was obtained from strain A1 by adaptation to 167 
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increasing concentrations of bile salts in our laboratory, followed by successive sub-cultivations 168 
without selective agent. Indeed we have proved that bile salts trigger the synthesis of EPS in this 169 
species [54]. The production of more than one EPS-fraction was also detected in B. breve 170 
NCIMB8807 cultivated in milk, which synthesised two polymers differing in size (EPS 1 = 1.2x10
6
 171 
Da and EPS 2 = 6.4x10
5
 Da) and in monosaccharide composition [46]. Similar to B. animalis subsp. 172 
lactis, the EPS synthesised by several strains of B. pseudocatenulatum showed similar 173 
monosaccharide ratio and composition (Table 1). In contrast, EPS synthesised by B. longum strains 174 
showed a wide distribution in their monosaccharide ratio. Galactose and glucose were present in 175 
most of them in variable proportions, with the exception of EPS synthesised by strain YIT4028; 176 
whereas, rhamnose was detected in half of the B. longum HePS (Table 1). In this regard, it was 177 
found that this monosaccharide was present in 48% of the HePS characterised from bifidobacteria 178 
to date. We have previously reported that the rhamnose content in EPS synthesised by lactobacilli 179 
and bifidobacteria of human origin was higher than in EPS synthesised by LAB strains of food 180 
origin: 52% in 21 human-origin EPS and 28% in 25 food-origin EPS [59]. Besides, to date only two 181 
described LAB- or bifido-polymers have an unusually high rhamnose content in their structural 182 
repeating unit, as determined by NMR technique; these are the heptasaccharide synthesised by 183 
Lactobacillus rhamnosus RW-9595M [69] and the HMW hexasaccharide synthesised by B. 184 
animalis subsp. lactis IPLA-R1 [31]. However, to the best of our knowledge, the biological 185 
relevance that a high rhamnose content in HePS from non-food origin could have, is still unknown.  186 
 187 
2. Immune modulation of EPS from LAB and bifidobacteria  188 
Apart from the ecological relevance that EPS may have for the producing bacteria and their 189 
industrial applications, there is increasing evidence to suggest a role for bifido- and LAB-EPS in the 190 
interaction between producing-bacteria and the (human) host, and therefore, exerting an impact on 191 
human health. It has been claimed that some EPS reduce cholesterol levels, act as fermentable 192 
(prebiotic) substrates for intestinal microbiota and modulate the immune response [55]. However, it 193 
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is well known that not all EPS are able to improve the technological properties of fermented foods 194 
[20] or to promote health benefits [2]. Therefore, the physico-chemical characteristics of EPS must 195 
be the key parameters determining their biological and functional properties.   196 
Several works in literature report the ability of EPS synthesised by LAB and bifidobacteria 197 
to elicit immune responses (Table 2). In an attempt to correlate some physico-chemical traits of EPS 198 
with their immune-modulating capability, we have detected two association patterns. First, it seems 199 
that acidic HePS, which are characterised as having phosphate (i.e. negative charge) in their 200 
composition, are good inducers of the immune response. This fact was illustrated by the HePS 201 
synthesised by LAB used as starters in the dairy food industry, such as the strain Lactococcus lactis 202 
subsp. cremoris KSV20 involved in the manufacture of the Scandinavian fermented milk viili. The 203 
viilian-HePS was able to induce the synthesis of IFN and IL-1 in mouse spleen macrophages 204 
cultivated in vitro [25]. The repeating unit of KSV20 HePS is a pentasaccharide composed of 205 
glucose- galactose- rhamnose in ratio 2:2:1, with the side-chain -D-galactopyranose substituted 206 
with PO4
- 
[42]. Similarly, Lb. delbrueckii subsp. bulgaricus OLL-1073-R1 synthesises an HePS 207 
composed of two fractions, acidic and neutral, both containing glucose and galactose (ratio 3:2) but 208 
the acid-fraction additionally having 0.1% PO4
- 
[67].  The acid fraction was a strong inducer of 209 
proliferation and activity of different macrophages, whereas the neutral-fraction was not able to 210 
elicit stimulation [26, 44]. Furthermore, the same authors have proved that phosphate was the 211 
molecule triggering the immune response, since the chemical dephosphorylation of this HePS 212 
encompasses a reduction in the stimulatory effect [26].  The relevant role of PO4
-
 in immune 213 
stimulation was also proven using the -glucan HoPS (dextran) synthesised by Leuconostoc 214 
mesenteroides as a model. When dextran was chemically phosphorylated, the proliferation of 215 
lymphocyte subsets from the murine spleen, as well as the gene expression of IFN and IL-10, 216 
directly augmented with the phosphate content [61]. 217 
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The second association pattern was detected for those HePS having big size or HMW, which 218 
seem to act as suppressors of the immune response (Table 2). One of the first examples illustrating 219 
this fact was reported by Yasuda and co-workers [79] using Lactobacillus casei Shirota as a model. 220 
This strain harbours an eps-cluster of 10 genes which is involved in the synthesis of a HMW (cell-221 
wall) polysaccharide; knockout-mutants of eps genes were able to induce the production of TNF, 222 
IL-12, IL-10 and IL-6, by mouse macrophage (RAW-264.7) cell line or by mouse spleen cells, to a 223 
higher extent than the wild-type bacterium. Thus, the authors concluded that the EPS synthesised by 224 
L. casei Shirota act by reducing excessive reaction of immune cells not only against its own 225 
stimulating components, but also against other inducers such as LPS. Similarly, murin peritoneal 226 
macrophages stimulated with the HMW-EPS-producing L. rhamnosus RW-9595M, an isogenic 227 
variant of the strain ATCC9595, induced low levels of TNF and IL-6; whereas, the parental L. 228 
rhamnosus ATCC9595 strain induced high levels of TNF, IL-6 and IL-12 and showed decreased 229 
IL-10 production [4]. We have also detected immune suppression upon human peripheral blood 230 
mononuclear cells (PBMC) induced by the HMW-EPS-producing Lactobacillus paraplantarum 231 
BGCG11, in comparison with its isogenic EPS
-
 mutants [43]. Recently, Fanning and co-workers 232 
[14] reported similar behavioural patterns in Bifidobacterium genus, using the approach of wild / 233 
KO-mutants of B. breve UCC2003 in murin in vitro and in vivo models. Naïve spleen cells 234 
stimulated with the EPS
+ 
(wild strain) had significantly lower levels of pro-inflammatory cytokines 235 
(IFN, TNF and IL-12) compared with those of the isogenic B. breve EPS- mutants. Additionally, 236 
the type and percentage of immune spleen cells examined from mice fed with the EPS
+
 strain were 237 
similar to that of untreated mice. On the contrary, mice fed with EPS
-
 strains increased the number 238 
and the percentage of different immune-subset cells in comparison with untreated mice. The 239 
expression of the cytokines produced by these cells also differed among the mice groups (feed 240 
placebo, EPS
+
 or EPS
-
). The authors concluded that the strain B. breve UCC2003, which 241 
synthesises an EPS, whose physico-chemical composition has not been reported yet but seems to 242 
have big size, was able to evade some adaptive B-cell responses.  243 
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The studies indicated above report the immune effect of the EPS-producing bacteria, but 244 
only a few works have effectively demonstrated the ability of purified HePS to elicit immune 245 
response. Our group has recently shown that human PBMC cultivated in the presence of EPS 246 
isolated from 10 bifidobacteria strains display specific cytokine profiles; that is, chemically 247 
different EPS were able to elicit different immune responses [32]. Especially relevant are the results 248 
obtained with the HePS purified from the three closely related B. animalis subsp. lactis strains 249 
mentioned above: A1 (parental), A1dOx (bile-adapted derivative) and A1dOxR (bile-adapted 250 
derivative having ropy phenotype). The EPS A1dOxR (at 1 g/ml) elicited lower production of 251 
cytokines by human PBMC than the EPS A1 or A1dOx, therefore suggesting an immune-252 
suppressive profile of the former. Additionally, when these HePS-producing B. animalis subsp. 253 
lactis strains were co-cultivated with colonocyte-like cells (Caco2) they elicited different cytokine 254 
patterns (unpublished results, Figure 1). The ropy A1dOxR strain induced significantly lower levels 255 
of pro-inflammatory IL-6 and IL-8 cytokines than the control (Caco2 cultivated in DMEM), 256 
whereas A1 induced the secretion of elevated amounts of these molecules, suggesting an immune 257 
activating role of the parental strain. On the other hand, Caco2 cells did not modify significantly IL-258 
1 production after culture with any bacterial strain; however, treatment with A1 and A1dOx 259 
showed a tendency to decrease its levels whereas an inverse trend was observed with A1dOxR, the 260 
production being significantly higher when compared with the other two strains. Given the 261 
relevance of IL-1 in the generation of Th17 cells, involved in mucosal defence and Treg/Th17 262 
plasticity, these data could suggest a role of the ropy A1dOxR strain in the immune homeostasis in 263 
the gut. In this regard, the EPS A1dOxR is a polymer composed of three EPS-fractions of different 264 
size: HMW (3.5x10
6
 Da), middle weight (3.0x10
4
 Da) and low weight (4.9x10
3
 Da) [31]; whereas, 265 
the other two related EPS (A1 and A1dOx) lack the HMW fraction [57]. Therefore, it seems that the 266 
presence of the HMW fraction could be responsible for the immune suppression capability of EPS 267 
A1dOxR. In this regard, the findings of Bleau and co-workers [4] also reinforce this idea since 268 
intermediate polymer chains (16-30 units, molecular weight < 10
4
 Da) obtained after hydrolysis of 269 
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the HMW-EPS (size 5.3x10
5
 Da) RW-9595M showed increased production of IL-10 by 270 
macrophages, in comparison with the native polymer synthesised by L. rhamnosus. It is worth 271 
noting that another common trait between the HMW-EPS A1dOxR (from B. animalis subsp. lactis) 272 
and the native EPS RW-9595M (from L. rhamnosus) is the high presence of rhamnose (more than 273 
50%) in the composition of their repeating units [31, 69]. At the moment, it is unknown if this 274 
characteristic could also be relevant to regulate the immune response.    275 
Finally, some works have been carried out regarding the immune activity of -glucans 276 
(HoPS-type) produced by LAB [17] and Propionibacterium;, this last genus belonging to 277 
Actinobacteria phylum, as bifidobacteria, and specific species are relevant for the sensorial 278 
properties of some cheeses [9]. Bacterial -glucans, which have a common structure of branched 279 
(13)--D-glucose substituted at C2 with -D-glucose (Table 2), act by modifying the response of 280 
PBMC since it seems that KO-mutants are able to relieve the immune suppression elicited by the 281 
wild type strains. Similarly, -glucans from fungus Sclerotium, having the same monomer 282 
composition, but differing in size and spatial conformation, are able to elicit variable proliferation in 283 
human monocyte cultures [13]. Therefore, it seems that the size of EPS polymers, either HePS or 284 
HoPS is of special relevance for their immune properties. 285 
Information about immune mechanism(s) elicited by bacterial EPS at molecular level is still 286 
scarce and, as far as we know, at present it is unknown for bifido- or LAB-EPS. In relation with 287 
other microbial EPS, it seems that some fungi glucuronoxylomannans (GXM) interact with the 288 
immune system through different Toll-like Receptors (TLR), also inducing production of nitric 289 
oxide by phagocytes [18]. In these fungal EPS the diameter of the molecule may potentially 290 
influence the inflammatory response against the GXM-producing fungi Cryptococcus [18, 80], as 291 
previously stated for Sclerotium -glucans [13]. Regarding bacteria, it has recently been 292 
demonstrated that the zwitterionic polysaccharide A (or PSA) produced by Bact. fragilis can 293 
suppress in vivo the pro-inflammatory IL-17 production by intestinal immune cells induced by 294 
Helicobacter hepaticus [35]. This PSA has the ability to induce Foxp3
+
 Treg cells, which produce an 295 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
increase of anti-inflammatory cytokines such as IL-10, and it seems that this induction is mediated 296 
by TLR-2 [51]. These authors propose that the immune system can discriminate between pathogens 297 
and predominant members of the commensal microbiota via recognition of molecules such as EPS 298 
[52]. Based on our findings and those reported in the literature, we propose a hypothetical 299 
mechanism(s) of action for HMW-EPS synthesized by bifidobacteria (Figure 2). The presence of 300 
HMW-EPS A1doXR at the mucosal surfaces could induce the generation of dendritic cells with a 301 
tolerogenic function by different mechanisms, not well known, but which could include the 302 
production of specific cytokines. These tolerogenic dendritic cells also secreted immunosuppressive 303 
cytokines and then the resultant cytokine network could mediate the induction and/or the expansion 304 
of regulatory T cells (probably FOXP3
+
CD25
high 
Treg) which in turn will control an excessive 305 
effector T cell (Teff) response or, in the presence of a specific cytokine environment, might trans-306 
differentiate into Th17 cells, thus maintaining mucosal defence and homeostasis. 307 
 308 
3. Conclusion  309 
In summary, base on literature data we propose that EPS having negative charge (phosphate 310 
in its composition) and/or having small size are able to act as mild stimulators of different immune 311 
cells; whereas, neutral and big-size (near 10
6
 Da) polymers have a suppressive profile, or could 312 
attenuate an excessive response, thus helping the producing bacteria to evade the immune response 313 
of the host. Nevertheless, although there is some evidence supporting this hypothesis, further 314 
research is needed in order to demonstrate which are the key physico-chemical parameters 315 
determining the ability of bifido- and LAB-EPS to modulate the immune response. Also, the 316 
mechanism(s) of action through the putative mediation of Foxp3
+
 Treg cells induction, or whether 317 
other pathways could be plausible, deserves further investigation.  318 
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Figure Legends 572 
Figure 1 Concentration (pg/ml) of some cytokines produced by Caco2 cells (in confluent and 573 
differentiated monolayer state) co-cultivated (for 8 h at 37ºC, 5% CO2) with three closely related B. 574 
animalis subsp. lactis strains (ratio Caco2: bacteria, 1: 10): A1 (white bar), A1dOx (light grey bar) 575 
and A1dOxR (dark grey bar). The black bar represents the control (Caco2 cultivated with DMEM 576 
antibiotic-free medium). The experimental design and material used was similar to that showed in 577 
Lopez and co-workers [32]. Cytokines were measure by means of ELISA tests (R&D Systems 578 
Europe Ltd., UK) and values depicted are the mean and standard deviation of three independent co-579 
culture replicates. Data were analysed by means of one-way ANOVA (SPSS/PC 15.0 software 580 
package, SPSS Inc., USA). For each cytokine, differences (p<0.05) between each strain with 581 
respect to the control are represented by an asterisk; differences among the three strains were 582 
assessed by a mean comparison test LSD (less significant difference) and bars that do not share a 583 
common letter are significantly (p<0.05) different.  584 
Figure 2 Hypothesis for immune suppression elicited by the high molecular weight (HMW)-EPS 585 
from B. animalis subsp. lactis A1dOxR. The capability to activate naïve CD4
+
 T cells through 586 
dendritic cells (DC) presenting EPS molecules has been demonstrated for specific (“zwitterionic”) 587 
polymers [50, 51, 52], although this way seems to be less plausible for non-charged EPS (a). In the 588 
B. animalis subsp. lactis strain, and in accordance with our preliminary in vitro [32] and in vivo 589 
(unpublished) data, the presence of HMW-EPS A1doXR could induce the activation and 590 
differentiation of DC, resulting in a cytokine (CK) production pattern that promote the  generation 591 
of tolerogenic DC. This tolerogenic DC and the CK environment could mediate the differentiation 592 
of naïve T cells into regulatory T cells (probably FOXP3
+
CD25
high 
Treg) that would drive the  593 
control of an excessive effector T cells (Teff) response or, in the presence of specific CK 594 
environment, might trans-differentiate into Th17 cells (b). Additionally, this strain was able to 595 
reduce the release of pro-inflammatory cytokines (Il-6 and IL-8) by enterocyte-like cells (c, Figure 596 
1).    597 
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Table 1 Main monosaccharides present in the HePS synthesised by the Bifidobacterium genus. 598 
Those present in LAB-HePS have been previously published [56]. 599 
 600 
  Monosaccharide ratio   
Species Strain Glc Gal Rha Repeated unit Reference 
B. animalis C64MRa 2.5 1.5 1 Unknown [59] 
 E43 2.5 2 1 Unknown [59] 
 A1 2.5 2 1 Unknown [57] 
 IPLA-R1 (A1dOxR) 1 1 1.5 Unknown [57] 
 HMW-IPLA-R1
a
 1 2 3 Hexa-saccharide [31] 
B. bifidum BIM B-465 1.3 1  Hepta-saccharide [81] 
 ALM35 1 3 2.4 Unknown [46] 
B. breve YIT4010 1.5 1  Penta-saccharide [19] 
 NCIMB8807-EPS1 2.5 1 1.4 Unknown [46] 
 NCIMB8807-EPS2 1 1.9  Unknown [46] 
B. catenulatum YIT4016  1  Tri-saccharide [40] 
B. longum subsp. longum ATCC15707
T
 1 1  Unknown [1] 
B. longum subsp. infantis ATCC15697
T
 b 1  Di-saccharide [65] 
B. longum  YIT4028  1.5 1 Penta-saccharide [41] 
 BB-79 1 1.5  Unknown [48] 
 JBL05 2 4 1 Hepta-saccharide [27] 
 H73 2.5 1 2 Unknown [59] 
 L55 4 1 1 Unknown [59] 
 H67 4 1 4 Unknown [59] 
 E44 1 1  Unknown [59] 
 CCUG52486 1.3 1  Unknown [46] 
 NCIMB702205 1 2.5  Unknown [46] 
 NB667 1 2.2 1 Unknown [60] 
 N667dCo 1.2 2.3 1 Unknown [60] 
B. pseudocatenulatum A102 2 1  Unknown [59] 
 C52 1 1  Unknown [59] 
 E515 2 1  Unknown [59] 
 E63 1 1  Unknown [59] 
 H34 1.5 1  Unknown [59] 
a 
HMW-IPLA.R1: high molecular weight fraction of EPS IPLA-R1 601 
b
 backbone: 3)--D-Galf-(13)--D-Galp-(1, which are partially substituted at O-6 with -D-602 
Glcp. 603 
 604 
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Table 2 Immune responses elicited by the EPS synthesised by bacteria present in foods (updated from Ruas-Madiedo et al., 2009b). 605 
Producing-bacterium Bacterial strain characteristic EPS characteristic
a
 Immune response Study modelb Reference 
Lactococcus lactis subsp.  
cremoris 
 KVS20 
 
 HePS, acid (2.2% PO4), high Mw  Stimulation In vitro mice spleen 
macrophages 
[25] 
Lactobacillus delbrueckii subsp.  
bulgaricus 
 OLL-1073R-1  HePS, acid fraction (0.1% PO4), high Mw 
 HePS, neutral fraction 
 Strong stimulation 
 Weak stimulation 
In vitro mice spleen 
cells and PPL 
[26] 
Leuconostoc mesenteroides  Commercial dextran 
 
 HoPS, -glucan (dextran) 
 HoPS, P-dextran (1.7% PO4) 
 Weak stimulation 
 Strong stimulation 
In vitro mice spleen 
macrophages 
[61] 
Lactobacillus kefiranofaciens  ATCC 46761 
 
 HePS (kefiran)  Stimulation In vivo  mice model [74] 
Bifidobacterium longum  BCRC 14634  Unknown   Mild modulator In vitro macrophage 
mice J77A.1 cell line 
[77] 
Lactobacillus casei  YIT 9019 (Shirota, parental) 
 KO-mutants   
 HePS, high Mw + low MW 
 (HePS, low MW?) 
 Suppression  
 Stimulation 
In vitro mice spleen 
cells and mice 
macrophage cell line 
[79] 
Lactobacillus rhamnosus  ATCC9595 (parental) 
 RW-9595M (derivative) 
 HePS ( rham) 
 HePS ( rham), high MW 
 Stimulation 
 Suppression 
In vitro mice 
macrophages  
[4] 
Bifidobacterium animalis subsp. 
lactis 
 A1 (parental, food origin) 
 A1dOx (bile adapted) 
 A1dOxR (bile adapted, ropy) 
 HePS, low Mw 
 HePS, low Mw 
 HePS ( rham), low Mw + high Mw  
 Stimulation 
 Stimulation 
 Suppression 
In vitro human 
PBMC 
[32] 
Bifidobacterium breve  UCC 2003 (parental EPS+) 
 UCC2003-EPS- variants  
 HePS 
 no production 
 Suppression  
 Stimulation 
In vivo mice model 
In vitro spleen cells 
[14] 
Pediococcus parvulus   2.6R (ropy, parental) 
 2.6NR (isogenic non-ropy mutant) 
 HoPS, 2-substituted (13)--glucan  
 no production 
 Suppression 
 Stimulation 
In vitro polarized 
human macrophages 
[17] 
Propionibacterium freudenreichii  CB1 (=TL34) (parental) 
 CB1-KO (gtf inactivated) 
 HoPS, 2-substituted (13)--glucan 
 no production 
 Suppression 
 Stimulation 
In vitro human 
PBMC 
[9] 
a
 HePS, heteropolysaccharide;  HoPS, homopolysaccharide; Rham, rhamnose; Gal, galactose; MW, molecular weight;  606 
b 
PPL, Payer´s Patches Lymphocytes; PBMC, peripheral blood mononuclear cells 607 
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Figure 2
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